Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01393483 · ClinicalTrials.gov registry record

Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)

A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
371
Enrollment target

NCT01393483: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT01393483 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 371 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01393483 has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
371 participants
Enrollment target

Study Summary

The purpose of this study is to find out whether a protein, called mesothelin, found in the blood and tissue can be used as "marker" for esophageal cancer. Doctors at Memorial Sloan-Kettering Cancer Center would like to compare levels of this protein in patients with abnormal cells or tissue of the esophageal to the levels of this protein in patients being treated for cancer for the esophagus.

Interventions

  • OTHER serum and tissue mesothelin

Trial Details

FieldValue
Enrollment Target 371 participants
Start Date 2011-03
Est. Completion 2024-10-22

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT01393483

The ClinicalTrials.gov registry entry for NCT01393483 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 371 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which serum and tissue mesothelin is the first listed.

NCT01393483 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01393483 about?

NCT01393483 is a clinical study titled "Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)". The purpose of this study is to find out whether a protein, called mesothelin, found in the blood and tissue can be used as "marker" for esophageal cancer. Doctors at Memorial Sloan-Kettering Cancer Center would like to compare levels of this protein in patients with abnormal cells or tissue of the ...

What is the current status of trial NCT01393483?

This trial is currently completed. The enrollment target is 371 participants. The study started on 2011-03. Estimated completion is 2024-10-22.

What interventions are being tested in trial NCT01393483?

The interventions under investigation include: serum and tissue mesothelin (OTHER).

Who is sponsoring clinical trial NCT01393483?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.